3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
18
Neoplasm Metastasis
14
Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Recurrence
9
Ovarian Neoplasms
7
Skin Neoplasms
6
Head and Neck Neoplasms
5
Carcinoma, Squamous Cell
5
Carcinoma, Renal Cell
5
Carcinoma, Basal Cell
5
Triple Negative Breast Neoplasms
4
Fallopian Tube Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Multiple Myeloma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Merkel Cell
3
Adenocarcinoma
3
Sarcoma
2
Pancreatic Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Glioma
2
Interventions
pembrolizumab
3
enzalutamide
2
blinatumomab
2
abiraterone
2
Immune Checkpoint Inhibitors
2
Cytochrome P-450 Enzyme System
2
AMG 757
2
durvalumab
1
dostarlimab
1
cemiplimab
1
atezolizumab
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Hydroxyurea
1
Etoposide
1
Etanercept
1
Carboplatin
1
Androgen Receptor Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bites and Stings
×
cemiplimab
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled